(Photo: iStock)

Indian pharmaceutical giant Zydus Cadila on Monday (April 5) sought approval from India’s drug regulator for additional indication of its hepatitis drug Pegylated Interferon Alpha-2b for treating Covid-19.

“Phase-III clinical trials with Pegylated Interferon Alpha 2b, which company sells under the brand name ‘PegiHep’ has shown promising results in treating Covid-19,” Zydus Cadila said in a statement.

The interim results indicate that the drug when administered early on, could help patients recover faster and avoid much of the complications seen in the advanced stages of the disease, it added.

“The treatment regimen would be less cumbersome and more affordable for patients as Pegylated Interferon Alpha 2b, is a single dose regimen. It would also ensure better compliance,” Zydus Cadila said.

PegIFN has very well-established safety with multiple doses in chronic Hepatitis B and C patients since many years, the drug producer added.

Patients on Pegylated Interferon Alpha 2b during the trial also showed lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating Covid-19, the company said in its statement.

“With these positive results, the company has applied for an approval for additional indication with DCGI for the use of PegIFN in the treatment of Covid 19,” it noted.

The phase-III trials were conducted on 250 patients across 20-25 centres in India and the detailed results of this will be published in a peer-reviewed scientific journal, the company said.

Zydus Cadila Healthcare MD Sharvil Patel said: “We are encouraged by the results of phase-III study of Pegylated Interferon Alpha 2b which has confirmed the potential to reduce virus titres when given earlier in the disease.”

“With Indian innovation at the forefront helping the country fight the pandemic with diagnostics, vaccines and therapeutics, this marks an important milestone,” he added.

If you want to share your stories and/or experiences with us, please send an email to [email protected]

LEAVE A REPLY